Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients

Inclusion Criteria:

1. Patients who either completed the 12 months AOP2014 treatment arm of the PROUD-PVstudy, or are currently participating in the CONTINUATION-PV, and at the "EoT visit" (End of treatment visit) of the PROUD-PV study or two weeks after the last assessmentvisit of the CONTINUATION-PV study, fulfill at least one of the following criteria:

• Normalization of at least two out of three main blood parameters (Hct (Hematocrit), PLTs (Platelets) and WBCs (white blood cells) if these parameterswere moderately increased (Hct<50%, WBCs<20 x 109/L, PLTs<600 x 109/L) atbaseline visit of the PROUD-PV study, OR

• >35% decrease of at least two out of three main blood parameters (Hct, PLTs andWBCs) if these parameters were massively increased (Hct>50%, WBCs>20 x 109/L,PLTs >600 x 109/L), at baseline visit of the PROUD-PV study, OR

• Normalization of spleen size, if spleen was enlarged at baseline visit of thePROUD-PV study, OR

• Otherwise a clear, medically verified benefit from treatment with AOP2014 (e.g.normalization of disease-related micro-vasculatory symptoms, substantial decreaseof JAK2 (Januskinase 2) allelic burden).

2. Signed written ICF.

Exclusion Criteria: Withdrawal criteria, as specified in the PROUD-PV and CONTINUATION-PV studies, whichmandate treatment discontinuation.

1. Non-recovery from the AOP2014 related toxicities to the grade (usually, Grade I) whichallows continuation of the treatment.

2. HADS (Hospital Anxiety and Depression Scale) score of 11 or higher on either or bothof the subscales, and /or development or worsening of clinically significantdepression or suicidal thoughts.

3. Progressive and clinically significant increase of liver enzyme levels despite dosereduction, or if such increase is accompanied by increased bilirubin level, any signsor symptoms of a clinically significant autoimmune disease.

4. Clinically significant development of a new ophthalmologic disorder, or worsening of apre-existing one, during the study.

5. Loss of efficacy of AOP2014 or any comparable situation where no further benefits oftreatment continuation are expected by the investigator.